Tcelltech GmbH, a spin-out of the German Cancer Research Center (DKFZ), envisages developping a universal personalised adoptive cell therapy against all cancers (UNIPACT).
UNIPACT is based on two platform technologies:
(I) High performance gene expressing DNA vector (nanoSMAR)
(II) AI bioinformatics platform for reactive T cell receptor identification (selecTCR).
Managing Directors: Prof. Dr. Michael Platten, Dr. Edward Green, Dr. Richard Harbottle, Dr. Mathias Turwitt
HRB 745600 AG Mannheim
Company Details
- Employees
- 4
- Founded
- -
- Address
- Franz-Volhard Straße 5, Cubex One,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.tcelltech.eu/
- Keywords
- Cell Therapy, Cancer Vaccines, Non-viral Gene Delivery, T cell Receptor Identification, T cell Therapy, nanoSMAR.
- HQ
- Mannheim, Baden-Württemberg
Tcelltech Gmbh Questions
Tcelltech Gmbh's website is https://www.tcelltech.eu/
Tcelltech Gmbh's LinkedIn profile is https://de.linkedin.com/company/tcelltech
Tcelltech Gmbh has
4 employees.
View email and phone details for 4
employees at Tcelltech Gmbh.
Tcelltech Gmbh's industry is
Biotechnology Research
Tcelltech Gmbh's categories are Biotechnology Research
Tcelltech Gmbh's founding year is 2022
